Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free ITCI Stock Alerts $69.82 +0.10 (+0.14%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$69.44▼$70.0050-Day Range$64.37▼$75.6552-Week Range$45.50▼$76.11Volume7,164 shsAverage Volume779,192 shsMarket Capitalization$6.76 billionP/E RatioN/ADividend YieldN/APrice Target$81.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside16.8% Upside$81.42 Price TargetShort InterestHealthy3.42% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment1.40Based on 7 Articles This WeekInsider TradingSelling Shares$28.60 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.65) to $0.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector71st out of 939 stocksPharmaceutical Preparations Industry27th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.42, Intra-Cellular Therapies has a forecasted upside of 16.8% from its current price of $69.72.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.42% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Intra-Cellular Therapies has recently decreased by 10.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.0 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Intra-Cellular Therapies this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,599,096.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.65) to $0.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -47.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -47.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 11.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesMarch 12, 2024 | insidertrades.comInsider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells 6,450 Shares of StockMarch 24, 2024 | finance.yahoo.comIntra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%March 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership EnhancementsMarch 20, 2024 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 19, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Announces Executive Appointments and Leadership ChangesMarch 19, 2024 | msn.comIntra-Cellular Therapies promotes Michael Halstead to PresidentMarch 19, 2024 | globenewswire.comIntra-Cellular Therapies Announces Executive Appointments and Leadership ChangesMarch 28, 2024 | Huge Alerts (Ad)Trending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! March 16, 2024 | ca.finance.yahoo.comITCI Apr 2024 90.000 callMarch 12, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 SharesMarch 7, 2024 | finance.yahoo.comITCI Aug 2024 50.000 callMarch 6, 2024 | globenewswire.comIntra-Cellular Therapies to Participate in Three Upcoming Investor ConferencesMarch 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intra-Cellular Therapies Amid Positive Outlook for Caplyta’s MDD TrialFebruary 28, 2024 | finance.yahoo.comEVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies IncFebruary 27, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care ConferenceFebruary 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Intra-Cellular Therapies Amid Growth and Operational EfficiencyFebruary 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 23, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate UpdateFebruary 22, 2024 | benzinga.comIntra-Cellular Therapies Stock (NASDAQ:ITCI), Short Interest ReportFebruary 22, 2024 | msn.comIntra-Cellular Therapies misses Q4 estimatesFebruary 22, 2024 | finance.yahoo.comIntra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate UpdateFebruary 22, 2024 | gurufocus.comIntra-Cellular Therapies Inc (ITCI) Reports Robust Revenue Growth in 2023 EarningsFebruary 22, 2024 | globenewswire.comIntra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate UpdateFebruary 21, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: February EditionFebruary 21, 2024 | msn.comIntra-Cellular Therapies Q4 2023 Earnings PreviewSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$81.42 High Stock Price Target$101.00 Low Stock Price Target$62.00 Potential Upside/Downside+16.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-30.08% Pretax Margin-29.94% Return on Equity-23.02% Return on Assets-19.39% Debt Debt-to-Equity RatioN/A Current Ratio5.41 Quick Ratio5.31 Sales & Book Value Annual Sales$464.37 million Price / Sales14.53 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book11.34Miscellaneous Outstanding Shares96,810,000Free Float93,516,000Market Cap$6.75 billion OptionableOptionable Beta1.02 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael I. Halstead J.D. (Age 51)Executive VP, General Counsel & Secretary Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSApellis PharmaceuticalsNASDAQ:APLSCytokineticsNASDAQ:CYTKJazz PharmaceuticalsNASDAQ:JAZZBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsHighPoint Advisor Group LLCBought 3,199 shares on 3/26/2024Ownership: 0.003%PNC Financial Services Group Inc.Sold 239 shares on 3/22/2024Ownership: 0.004%Vanguard Group Inc.Bought 554,577 shares on 3/11/2024Ownership: 9.394%Sharon MatesSold 20,565 sharesTotal: $1.34 M ($65.21/share)Michael HalsteadSold 7,345 sharesTotal: $484,549.65 ($65.97/share)View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 10 analysts have issued 12 month price targets for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they expect the company's share price to reach $81.42 in the next year. This suggests a possible upside of 16.8% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2024? Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of the year. Since then, ITCI stock has decreased by 2.7% and is now trading at $69.72. View the best growth stocks for 2024 here. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 3,310,000 shares, a decline of 10.5% from the February 29th total of 3,700,000 shares. Based on an average daily volume of 798,300 shares, the short-interest ratio is presently 4.1 days. View Intra-Cellular Therapies' Short Interest. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14. The biopharmaceutical company had revenue of $132.10 million for the quarter, compared to analysts' expectations of $135.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 23.02% and a negative net margin of 30.08%. The firm's revenue was up 50.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.45) earnings per share. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.45%), Vanguard Group Inc. (9.39%), Wasatch Advisors LP (3.77%), Bellevue Group AG (3.19%), Avoro Capital Advisors LLC (2.34%) and Franklin Resources Inc. (1.85%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.